News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,107 Results
Type
Article (13844)
Company Profile (281)
Press Release (243982)
Section
Business (79298)
Career Advice (147)
Deals (13176)
Drug Delivery (32)
Drug Development (50259)
Employer Resources (31)
FDA (5670)
Job Trends (5115)
News (143966)
Policy (10023)
Tag
Academia (906)
Alliances (21439)
Alzheimer's disease (702)
Approvals (5636)
Artificial intelligence (50)
Bankruptcy (97)
Best Places to Work (4414)
Biotechnology (230)
Breast cancer (43)
Cancer (453)
Career advice (128)
CAR-T (37)
Cell therapy (127)
Clinical research (39374)
Collaboration (158)
Compensation (73)
COVID-19 (997)
C-suite (36)
Cystic fibrosis (61)
Data (431)
Diabetes (51)
Diagnostics (1181)
Earnings (28417)
Events (46169)
Executive appointments (138)
FDA (5858)
Featured Employer (37)
Funding (162)
Gene therapy (104)
GLP-1 (275)
Government (1059)
Healthcare (6536)
Infectious disease (1018)
Inflammatory bowel disease (85)
IPO (7161)
Job creations (857)
Job search strategy (124)
Layoffs (179)
Legal (1375)
Lung cancer (88)
Manufacturing (53)
Medical device (2536)
Medtech (2537)
Mergers & acquisitions (6065)
Metabolic disorders (172)
Neuroscience (861)
NextGen Class of 2024 (1985)
Non-profit (840)
Northern California (672)
Obesity (98)
Opinion (87)
Parkinson's disease (53)
Patents (39)
People (24844)
Pharmaceutical (46)
Phase I (13823)
Phase II (18303)
Phase III (11638)
Pipeline (111)
Postmarket research (847)
Preclinical (5825)
Radiopharmaceuticals (201)
Rare diseases (124)
Real estate (1406)
Regulatory (8110)
Research institute (937)
Southern California (641)
Startups (1965)
United States (5762)
Vaccines (146)
Weight loss (64)
Date
Today (97)
Last 7 days (357)
Last 30 days (1577)
Last 365 days (21078)
2024 (16560)
2023 (22421)
2022 (26846)
2021 (27826)
2020 (23378)
2019 (16261)
2018 (11752)
2017 (13759)
2016 (11849)
2015 (14369)
2014 (10407)
2013 (7493)
2012 (7546)
2011 (7626)
2010 (7434)
Location
Africa (147)
Arizona (40)
Asia (16722)
Australia (2811)
California (1549)
Canada (576)
China (116)
Colorado (53)
Connecticut (56)
Europe (35962)
Florida (164)
Georgia (40)
Illinois (93)
Indiana (49)
Kansas (54)
Maryland (233)
Massachusetts (1257)
Michigan (42)
Minnesota (77)
New Jersey (406)
New York (476)
North Carolina (359)
Northern California (672)
Ohio (67)
Pennsylvania (337)
South America (207)
Southern California (641)
Texas (148)
Washington State (175)
258,107 Results for "achilles therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Achilles Therapeutics Announces Strategic Update
September 19, 2024
·
6 min read
Business
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Achilles Therapeutics plc announced its financial results for the first quarter ended March 31, 2024, and recent business highlights.
May 8, 2024
·
7 min read
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), an mRNA medicines company, to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines (PCVs) targeting clonal neoantigens.
May 22, 2024
·
8 min read
Business
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
Achilles Therapeutics plc announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.
April 4, 2024
·
9 min read
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - May 17, 2024
Achilles Therapeutics plc disclosed that the Company received notice on May 16, 2024 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450.
May 17, 2024
·
3 min read
Press Releases
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
August 14, 2024
·
8 min read
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference.
February 5, 2024
·
1 min read
Drug Development
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Achilles Therapeutics plc announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.
April 4, 2024
·
6 min read
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
Achilles Therapeutics plc today announced publication of a ‘Comment’ in Nature Cancer that outlines the vast potential of neoantigen immunogenicity prediction, discusses current limitations in the field that limit performance, and proposes a path forward.
December 18, 2023
·
4 min read
Business
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.
November 13, 2023
·
7 min read
1 of 25,811
Next
